BioCentury
ARTICLE | Clinical News

PLX3397: Phase II start

December 15, 2014 8:00 AM UTC

Daiichi Sankyo’s Plexxikon Inc. subsidiary said PLX3397 will join the ongoing Phase II I-SPY 2 trial in 1H15 to treat patients with newly diagnosed, locally advanced breast cancer. I-SPY 2 is designed to rapidly and inexpensively test compounds in up to 8 biomarker-defined subgroups of patients with neoadjuvant breast cancer. The program uses Bayesian statistics to predict specific groups in which a compound has a =85% chance of success in a Phase III trial. ...